News » AACC selects Visby Medical as 2022 Disruptive Technology Award Finalist

06/15/2022Press Release

AACC selects Visby Medical as 2022 Disruptive Technology Award Finalist

AACC selects Visby Medical as a finalist for the 2022 Disruptive Technology Award for its handheld point-of-care PCR diagnostic technology.

AACC selects Visby Medical as 2022 Disruptive Technology Award Finalist

SAN JOSE, Calif, – June 15, 2022 – The American Association for Clinical Chemistry (AACC) announced Wednesday that they have selected Visby Medical as a finalist for the 2022 Disruptive Technology Award for its handheld point-of-care PCR diagnostic technology. The Company’s Founder and CEO Adam de la Zerda, Ph.D., will present the technology at the Disruptive Technology Award special session during the 2022 AACC Annual Scientific Meeting on Monday, July 25 in Chicago, Illinois.

“We are excited to present the world’s first instrument-free palm-sized rapid PCR platform to the AACC and illustrate how it is already being adopted by clinicians to transform the infectious disease treatment landscape,” said de la Zerda. “Our vision, to empower anyone to test for any infection anytime in any place, drives our mission to develop innovative technology to disrupt medical diagnostics. Our tests enable accurate results during the patient visit with their clinician, supporting data-informed diagnosis to end the need for presumptive treatment for these infections, the true value of POCT. It is an honor to be recognized.”

The Sexual Health Click Test is a handheld, instrument-free, polymerase chain reaction (PCR) diagnostic that detects Chlamydia, Gonorrhea and Trichomonas via self-collected vaginal swab and returns results in about 30 minutes. It is FDA-cleared and CLIA-waived for point of care use. Because the device is so small, deployable and single-use, the platform has the potential to benefit patients whose clinicians may not have access to high complexity labs.

About Visby Medical™
Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The Company’s proprietary technology development program culminated in the world’s first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. The Visby Medical technology is also helping to fight the global pandemic via the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. Visby Medical is accelerating the delivery of fast and accurate, palm-sized PCR diagnostics to the point of care, and eventually for use at home.

For more information, visit www.visbymedical.com. Follow Visby Medical on LinkedInFacebook, and Twitter.

Media Contact
Doug Hochstedler
press@visby.com

Read more articles & insights

06/12/2024Publication

Point-of-Care STI Test by Visby Medical Enables Faster, More Targeted Treatment in the Johns Hopkins Medicine Emergency Department

The study directly compared two approaches for female STI testing in the emergency department (ED).

Read More
Point-of-Care STI Test by Visby Medical Enables Faster, More Targeted Treatment in the Johns Hopkins Medicine Emergency Department

05/30/2024Press Release

Visby Medical™ Sexual Health Test Results in More Appropriate Antibiotic Treatment and Shorter Emergency Department Visits Than Standard of Care

Point-of-Care test significantly shortens time from ED arrival to test results, treatment and discharge – significant improvements are seen in the use of antibiotics for the treatment of chlamydia and gonococcal infections in women.

Nationwide increases in sexually transmitted diseases and antibiotic resistance create the need for a paradigm shift from traditional lab-based molecular testing.

Read More
Visby Medical™ Sexual Health Test Results in More Appropriate Antibiotic Treatment and Shorter Emergency Department Visits Than Standard of Care

04/05/2024Viewpoint

The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

In light of the rising rates of sexually transmitted infections (STIs), urgent care clinics have found themselves at a crucial crossroads. PCR (Polymerase Chain Reaction) testing at the point of care emerges as a potential game-changer.

Read More
The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

03/14/2024Viewpoint

Understanding the Financial Impact of PCR Point of Care Testing for STIs

The adoption of point-of-care polymerase chain reaction (PCR) testing represents a significant leap forward in diagnostic capabilities. With its promise of speed, accuracy, and efficiency, PCR testing technology is setting a new standard in patient care.

Read More
Understanding the Financial Impact of PCR Point of Care Testing for STIs